COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study

Archive ouverte

Belli, Luca Saverio | Duvoux, Christophe | Cortesi, Paolo Angelo | Facchetti, Rita | Iacob, Speranta | Perricone, Giovanni | Radenne, Sylvie | Conti, Sara | Patrono, Damiano | Berlakovich, Gabriela | Hann, Angus | Pasulo, Luisa | Castells, Lluis | Faitot, Francois | Detry, Olivier | Invernizzi, Federica | Magini, Giulia | de Simone, Paolo | Kounis, Ilias | Morelli, Maria Cristina | Díaz Fontenla, Fernando | Ericzon, Bo-Göran | Loinaz, Carmelo | Toso, Christian | Johnston, Chris | Gheorghe, Liliana | Lesurtel, Mickaël | Romagnoli, Renato | Kollmann, Dagmar | Perera, M Thamara Pr | Fagiuoli, Stefano | Mirza, Darius | Coilly, Audrey | Zieniewicz, Krzysztof | Elkrief, Laure | Karam, Vincent | Adam, Rene | den Hoed, Caroline | Merli, Marco | Puoti, Massimo | de Carlis, Luciano | Oniscu, Gabriel | Piano, Salvatore | Angeli, Paolo | Fondevila, Constantino | Polak, Wojciech

Edité par CCSD ; BMJ Publishing Group -

International audience. Objective Explore the impact of COVID-19 on patients on the waiting list for liver transplantation (LT) and on their post-LT course. Design Data from consecutive adult LT candidates with COVID-19 were collected across Europe in a dedicated registry and were analysed. Results From 21 February to 20 November 2020, 136 adult cases with laboratory-confirmed SARS-CoV-2 infection from 33 centres in 11 European countries were collected, with 113 having COVID-19. Thirty-seven (37/113, 32.7%) patients died after a median of 18 (10–30) days, with respiratory failure being the major cause (33/37, 89.2%). The 60-day mortality risk did not significantly change between first (35.3%, 95% CI 23.9% to 50.0%) and second (26.0%, 95% CI 16.2% to 40.2%) waves. Multivariable Cox regression analysis showed Laboratory Model for End-stage Liver Disease (Lab-MELD) score of ≥15 (Model for End-stage Liver Disease (MELD) score 15–19, HR 5.46, 95% CI 1.81 to 16.50; MELD score≥20, HR 5.24, 95% CI 1.77 to 15.55) and dyspnoea on presentation (HR 3.89, 95% CI 2.02 to 7.51) being the two negative independent factors for mortality. Twenty-six patients underwent an LT after a median time of 78.5 (IQR 44–102) days, and 25 (96%) were alive after a median follow-up of 118 days (IQR 31–170). Conclusions Increased mortality in LT candidates with COVID-19 (32.7%), reaching 45% in those with decompensated cirrhosis (DC) and Lab-MELD score of ≥15, was observed, with no significant difference between first and second waves of the pandemic. Respiratory failure was the major cause of death. The dismal prognosis of patients with DC supports the adoption of strict preventative measures and the urgent testing of vaccination efficacy in this population. Prior SARS-CoV-2 symptomatic infection did not affect early post-transplant survival (96%).

Consulter en ligne

Suggestions

Du même auteur

Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)

Archive ouverte | Belli, Luca | CCSD

International audience. Liver transplantation (LT) has been proposed as an effective salvage therapy even for the sickest patients with acute-on-chronic liver failure (ACLF). This large collaborative study was desig...

Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study

Archive ouverte | Belli, Luca | CCSD

International audience

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

Archive ouverte | Belli, Luca Saverio | CCSD

International audience. BACKGROUND & AIMS:All oral direct acting antivirals (DAA) have been shown to improve the liver function of patients with decompensated cirrhosis but it is presently unknown whether this clini...

Chargement des enrichissements...